Showing results (1221-1230 of 1,717) with videos related to

Sort By:
Pageof 172
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|January 24, 2024
Tumour deposits are independently associated with recurrence in colon cancerLynn Hakki, Asama Khan, Eric Do, et al.
Blood Cancer Journal|November 25, 2025
Optimizing lower intensity triplet therapy in acute myeloid leukemia: a practical guideWei-Ying Jen, Curtis A Lachowiez, Jennifer Marvin-Peek, et al.
Diseases of the Colon and Rectum|November 22, 2021
MRI at Restaging After Neoadjuvant Therapy for Rectal Cancer Overestimates Circumferential Resection Margin Proximity as Determined by Comparison With Whole-Mount PathologyJonathan B Yuval, Hannah M Thompson, Canan Firat, et al.
Blood|March 5, 2015
Inositol polyphosphate 4-phosphatase II (INPP4B) is associated with chemoresistance and poor outcome in AMLSewa Rijal, Shaun Fleming, Nik Cummings, et al.
Frontiers in Immunology|April 7, 2023
Abnormal thrombosis and neutrophil activation increase hospital-acquired sacral pressure injuries and morbidity in COVID-19 patientsJatin Narang, Samreen Jatana, András K Ponti, et al.
Science Translational Medicine|August 10, 2012
Instructive nanofiber scaffolds with VEGF create a microenvironment for arteriogenesis and cardiac repairYi-Dong Lin, Chwan-Yau Luo, Yu-Ning Hu, et al.
Diseases of the Colon and Rectum|September 14, 2022
Assessment of Patient-Reported Outcomes in Patients With Anal Squamous-Cell Cancer Undergoing Combined Modality TherapyJames P Taylor, Iris H Wei, J Joshua Smith, et al.
Blood|January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Cancer Cell|November 14, 2006
The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralizedMark F van Delft, Andrew H Wei, Kylie D Mason, et al.
Future Oncology (London, England)|March 14, 2020
MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemiaPau Montesinos, Benjamin M Beckermann, Olivier Catalani, et al.
Pageof 172